Surprising many in the medtech world, Abbott announced recently that they are partnering with Medtronic to design and manufacture a sensor for use with Medtronic's AID and smart insulin pen systems.
The new CGM sensor will be based on the FreeStyle Libre sensors but will operate only with Medtronic tech and be available from Medtronic.
Simplifying diabetes management with AID
AID systems are known for improving health outcomes by reducing the mental burden of constant decision-making for people with diabetes. The systems are particularly helpful for people who require multiple daily insulin injections. Data suggests that over 11 million people worldwide could benefit from AID technology.
The partnership aims to simplify the lives of those using insulin-intensive therapies by allowing the system to make real-time adjustments without the user having to constantly monitor their glucose levels or manually calculate insulin doses.
What the partnership means
"This partnership pairs two global leaders in glucose sensing and insulin delivery," said Jared Watkin, Executive Vice President of Abbott’s Diabetes Care division. He emphasized how Abbott’s FreeStyle Libre has set the standard for accurate, easy-to-use, and reliable CGM technology.
“By connecting this CGM to Medtronic’s insulin delivery systems, we’re making it easier for people to spend less time worrying about their diabetes and more time enjoying life,”.
Medtronic’s Executive Vice President and President of Diabetes, Que Dallara, echoed the sentiment:
"Our partnership with Abbott allows us to expand access to our advanced insulin delivery systems and integrate with the most widely used CGM in the world."
The collaboration underscores Medtronic’s commitment to making diabetes management simpler and more seamless for users transitioning to automated insulin delivery.
What’s next?
While the financial details of this partnership and the timeline for commercial availability have not been disclosed, this collaboration marks another step forward in streamlining diabetes care. Abbott’s Libre technology is already integrated with AID systems from other insulin delivery companies, and this new partnership with Medtronic aims to give users even more options for managing their diabetes confidently and efficiently.
This partnership is part of a broader effort by Abbott to expand its reach and improve the quality of life for people with diabetes by offering easy-to-use, reliable solutions for glucose monitoring and insulin delivery. As both companies continue to push the boundaries of diabetes care, the future looks promising for more advanced, integrated, and user-friendly technologies.
Reference
Disclaimer
Blogs and publications on this website are independent of any involvement by medtech companies or diabetes related charities. To ensure there is no bias, we do not accept any products, freebies or other material from any medtech provider. Except where credited otherwise, all materials are copyright ©️Love My Libre Ltd.
Love My Libre is not associated or affiliated with Abbott or FreeStyle Libre. Content here and on our website www.lovemylibre.com does not constitute medical advice or replace the relationship between you and healthcare professionals nor the advice you receive from them.
The author of this blog has type 1 diabetes and uses the FreeStyle Libre 2 which is provided on NHS prescription.
Leave a comment (all fields required). Please note, we are unable to respond to individual comments posted here.